Tuesday February 9 2010 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Image Results

Loading...
Loading...

CAMPATH Pages on BioPortfolio:

Biotechnology News CAMPATH Search
Biotechnology and Pharmaceutical Industry Search Find Companies, News, Events, Jobs, Directory.
http://www.bioportfolio.co.uk/CAMPATH-news.htm...

Campath Improves Survival of Refractory CLL Patients
Campath demonstrated encouraging data in terms of overall objective ... Campath is indicated for use for the treatment of B-CLL in patients who have failed ...
http://www.bioportfolio.com/news/btech_051502_2.htm...

Biotechnology News FDA EMEA CDER regulatory arzerra. genmab. glaxo ...
Current Search: fda: 13498, emea: 458, cder: 26, regulatori: 6442, arzerra: 78, genmab: 79, glaxo: 544, genco: 8, genzo: 15, campath: 19 ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=e...

BTG plc: Final Phase II Results of CampathR Multiple Sclerosis ...
23 Oct 2008 ... Results show a significant and sustained reduction in disability and risk of relapse for MS patients on Campath® versus those on Rebif® ...
http://www.bioportfolio.com/biotech_news/BTG_11.htm...

Biotechnology News FLUDARA Search
Genzyme Corporation (Nasdaq: GENZ) announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath (alemtuzumab) in combination with ...
http://www.bioportfolio.co.uk/FLUDARA-news.htm...

BioPortfolio Limited Forecast Insight: Multiple Sclerosis ...
Table 36: Multiple sclerosis-specific sales forecast ($m) for alemtuzumab ( Campath) in the seven major markets, 2007-17 96 ...
http://www.bioportfolio.com/cgi-bin/acatalog/info_496.html...

BioPortfolio.com - BioWeb Thrombocytopenia Search
Overview VELCADE ® Campath ® Research and Development Clinical Trials Resources for Patients MECHANISM PHASE 3 TRIAL DESIGN PHASE 3 TRIAL RESULTS ONLY 1 ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=s...



...

BioPortfolio.com - BioWeb Lymphopenia Search
FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER Package Insert Campath ® (ALEMTUZUMAB) Millennium and ILEX Partners, ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=s...

The Future of Monoclonal Antibody Therapeutics
Simulect, Zenapax and Campath. 98. Campath. 98. Others. 99. Innovation in antibody engineering. 99. New indications. 100. Challenges. 101. Generic
biologics ...
http://www.bioportfolio.com/cgi-bin/acatalog/The%20Future_of...

Results from other life science and pharmaceutical sites:

Alemtuzumab - Wikipedia, the free encyclopedia
The origins of alemtuzumab date back to Campath-1 which was derived from the ... This became known as Campath-1H and serves as the basis for alemtuzumab. ...
http://en.wikipedia.org/wiki/Alemtuzumab...

Buzz around Campath proof-of-concept trial in MS : Article ...
The next two years are expected to reveal much about not only Campath in MS, ... In the phase 2 trial, known as CAMMS223, Campath was administered once ...
http://www.nature.com/nbt/journal/v27/n1/full/nbt0109-6.html...

Alemtuzumab (marketed as Campath) Information
9 Sep 2009 ... This is a summary of the most important information about Campath. For more information, talk to your healthcare professional. ...
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInfo...

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol ...
CAMPATH-1 antibodies recognize a unique molecule on human lymphocytes and are unusually efficient at causing cell lysis with homologous complement. ...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1134413/...

Bone Marrow Transplantation - In vivo Campath for the prevention ...
1 Nov 2004 ... In vivo Campath for the prevention of GvHD following allogeneic HSCT: effects of dose, schedule and antibody type ...
http://www.nature.com/bmt/journal/v34/n12/full/1704695a.html...

Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth ...
The CAMPATH-1H (CD52) antigen is a 21 000-28 000 MW glycopeptide antigen that is highly expressed on T and B lymphocytes and is coupled to the membrane by a ...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1364410/...

Bone Marrow Transplantation - Successful use of Campath-1H in the ...
At this stage, he was treated with Campath-1H i.v. 10 mg/day on days 1–5 ... Response of liver GvHD to Campath-1H, showing marked improvement in liver ...
http://www.nature.com/bmt/journal/v34/n3/full/1704573a.html...

Mooren's ulcer resolved with campath-1H
Campath-1H is a humanised lymphocytotoxic monoclonal antibody (mAb) that targets the CD52 antigen on T lymphocytes. Successful mAb therapy using campath-1H ...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1771776/...

Information for Healthcare Professionals - Alemtuzumab (marketed ...
9 Sep 2009 ... Campath is not approved for the treatment of MS. Campath is approved for treating B-cell chronic lymphocytic leukemia (CLL) in patients who ...
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInfo...

CAMPATH: from concept to clinic
CAMPATH-1H (alemtuzumab) was generated in an attempt to replace anti-lymphocyte globulins in the transplant arena. Its efficacy in killing lymphocytes has ...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1569536/...

Google Custom Search

Search
  


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2010 - BioPortfolio Limited.